News & HighlightsNews
Why studying how the immune system evolves could teach us much about evolution itself
Gabriel D. Victora's team has turned germinal centers into a living laboratory for one of biology's oldest questions: how much of evolution is shaped by chance?
How the body creates reliable antibodies out of biological chaos
A new study reveals how germinal centers produce powerful antibodies through noisy rounds of mutation and selection, offering new insight into vaccine design—and larger themes in evolution.
Programming the immune system to manufacture its own therapeutic proteins
By editing blood stem cells, researchers show that the immune system itself can be transformed into a durable, boostable source of therapeutic proteins—opening the door to novel treatments
Studying two very different viruses is helping this virologist develop new strategies for more potent antiviral treatments
Theodora Hatziioannou used her expertise on HIV-1 to gain insights into SARS-Co-V-2, and vice versa. The potential applications of her insights could be much broader.
A protein thought to play a supporting role in DNA replication actually facilitates the whole process
Scientists have discovered that a protein once thought to simply help load a factor necessary for the copying of DNA, actually plays a key role in ensuring fast and reliable replication—an insight that could inform research into cancer and other diseases.
In rare cases, autoantibodies can cause severe reactions to a live-attenuated virus Chikungunya vaccine that has been discontinued in the U.S.
A new study shows that preexisting autoantibodies in a small subset of the population can allow weakened vaccine viruses to escape control, explaining some adverse events tied to this one kind of Chikungunya vaccine, which is no longer available in the U.S.
New engineered derivative of a natural molecule could translate into a powerful replacement for IVIG therapy for a wide array of autoimmune disorders
In experiments with mice, the new molecule accomplished the same job at a hundredth of the dose.
Rockefeller startup aims to change the course of treatment for severe autoimmune diseases
Nuvig, a biotech company cofounded by Jeffrey Ravetch, has launched phase two trials and raised $200 million.
Researchers develop a potential IVIG replacement for treating autoimmunity that’s significantly more potent
The discovery could greatly improve patient experience and address supply shortages.
There are countless species of bacteria scientists have never seen. This lab develops techniques that allow scientists to see them.
Their newest technique has already uncovered hundreds of hidden bacterial genomes and two promising antibiotics. Now, the same approach could unlock an entire microbial universe—reshaping drug discovery and our understanding of how bacteria shape our environment.
View
View